![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Current treatments for the parasitic disease leishmaniasis are unsatisfactory due to their route of administration, toxicity and expense. Resistance is also developing to first-line antimonial drugs. Recently, the efficacy of some low-cost generic drugs was verified, their mechanism of action elucidated and the manner in which the parasites become resistant to the drugs determined. This review presents a synopsis of the patents and lead compounds that have been investigated over the last 4 years against leishmaniasis, giving a perspective on the chemotherapeutic potential of each, and discusses some of the obstacles to antileishmanial drug development.